{"count": 8, "results": [{"_id": "35629125", "pmid": 35629125, "pmcid": "PMC9144588", "title": "Role of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes", "journal": "J Pers Med", "authors": ["Yen FS", "Wei JC", "Shih YH", "Pan WL", "Hsu CC", "Hwu CM"], "date": "2022-04-28T00:00:00Z", "doi": "10.3390/jpm12050702", "meta_date_publication": "2022 Apr 28", "meta_volume": "12", "meta_issue": "5", "meta_pages": "", "score": 50282.19, "text_hl": "Our study showed no significant difference in @<m>DISEASE_Urinary_Tract_Infections</m> @DISEASE_MESH:D014552 @@@UTI@@@ and recurrent @<m>DISEASE_Urinary_Tract_Infections</m> @DISEASE_MESH:D014552 @@@UTI@@@ risk between @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use versus nonuse. ", "citations": {"NLM": "Yen FS, Wei JC, Shih YH, Pan WL, Hsu CC, Hwu CM. Role of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes J Pers Med. 2022 Apr 28;12(5):. PMID: 35629125", "BibTeX": "@article{35629125, title={Role of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes}, author={Yen FS and Wei JC and Shih YH and Pan WL and Hsu CC and Hwu CM}, journal={J Pers Med}, volume={12}, number={5}}"}}, {"_id": "37891260", "pmid": 37891260, "pmcid": "PMC10611756", "title": "Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients", "journal": "Sci Rep", "authors": ["Park S", "Jeong J", "Woo Y", "Choi YJ", "Shin S"], "date": "2023-10-27T00:00:00Z", "doi": "10.1038/s41598-023-45793-x", "meta_date_publication": "2023 Oct 27", "meta_volume": "13", "meta_issue": "1", "meta_pages": "18462", "score": 50249.492, "text_hl": "Interestingly, in a previous study on Japanese @SPECIES_9606 @@@patients@@@, @GENE_DPP4 @GENE_1803 @@@DPP-4@@@ inhibitors also showed protective effects against @<m>DISEASE_Urinary_Tract_Infections</m> @DISEASE_MESH:D014552 @@@UTIs@@@ relative to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ with the intention-to-treat hazard ratio (HR) of 0.85 (0.71-0.94) and the per-protocol HR of 0.83 (0.71-0.95). ", "citations": {"NLM": "Park S, Jeong J, Woo Y, Choi YJ, Shin S. Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients Sci Rep. 2023 Oct 27;13(1):18462. PMID: 37891260", "BibTeX": "@article{37891260, title={Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients}, author={Park S and Jeong J and Woo Y and Choi YJ and Shin S}, journal={Sci Rep}, volume={13}, number={1}, pages={18462}}"}}, {"_id": "35005849", "pmid": 35005849, "pmcid": "PMC8929338", "title": "Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea", "journal": "Pharmacol Res Perspect", "authors": ["Yang H", "Choi E", "Park E", "Na E", "Chung SY", "Kim B", "Han SY"], "date": "2022-02-01T00:00:00Z", "doi": "10.1002/prp2.910", "meta_date_publication": "2022 Feb", "meta_volume": "10", "meta_issue": "1", "meta_pages": "e00910", "score": 50247.06, "text_hl": "Risk of @<m>DISEASE_Urinary_Tract_Infections</m> @DISEASE_MESH:D014552 @@@genital and urinary tract infections@@@ associated with @GENE_SLC5A2 @GENE_6524 @@@SGLT-2@@@ inhibitors as an add-on therapy to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@: A retrospective cohort study in Korea", "citations": {"NLM": "Yang H, Choi E, Park E, Na E, Chung SY, Kim B, Han SY. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea Pharmacol Res Perspect. 2022 Feb;10(1):e00910. PMID: 35005849", "BibTeX": "@article{35005849, title={Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea}, author={Yang H and Choi E and Park E and Na E and Chung SY and Kim B and Han SY}, journal={Pharmacol Res Perspect}, volume={10}, number={1}, pages={e00910}}"}}, {"_id": "24186878", "pmid": 24186878, "pmcid": "PMC3836134", "title": "Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin", "journal": "Diabetes Care", "authors": ["Ferrannini E", "Berk A", "Hantel S", "Pinnetti S", "Hach T", "Woerle HJ", "Broedl UC"], "date": "2013-12-01T00:00:00Z", "doi": "10.2337/dc13-0663", "meta_date_publication": "2013 Dec", "meta_volume": "36", "meta_issue": "12", "meta_pages": "4015-21", "score": 50064.676, "text_hl": "AEs consistent with @<m>DISEASE_Urinary_Tract_Infections</m> @DISEASE_MESH:D014552 @@@urinary tract infections@@@ were reported in 3.8-12.7% of @SPECIES_9606 @@@patients@@@ on @CHEMICAL_empagliflozin @CHEMICAL_MESH:C570240 @@@empagliflozin@@@, 3.6% on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, and 12.5% on @CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitagliptin@@@.", "citations": {"NLM": "Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC. Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin Diabetes Care. 2013 Dec;36(12):4015-21. PMID: 24186878", "BibTeX": "@article{24186878, title={Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin}, author={Ferrannini E and Berk A and Hantel S and Pinnetti S and Hach T and Woerle HJ and Broedl UC}, journal={Diabetes Care}, volume={36}, number={12}, pages={4015-21}}"}}, {"_id": "34860970", "pmid": 34860970, "title": "Pharmacovigilance of Sodium-Glucose Cotransporter-2 Inhibitors for Genital Fungal Infections and Urinary Tract Infections: A Review of the Food and Drug Administration Adverse Event Reporting System Database.", "journal": "J Pharm Technol", "authors": ["Mohammad H", "Borja-Hart N"], "date": "2018-08-01T00:00:00Z", "doi": "10.1177/8755122518760984", "meta_date_publication": "2018 Aug", "meta_volume": "34", "meta_issue": "4", "meta_pages": "144-148", "score": 50048.473, "text_hl": "A total of 727 cases related to @<m>DISEASE_Urinary_Tract_Infections</m> @DISEASE_MESH:D014552 @@@UTIs@@@ were reported (6% of reports submitted): @CHEMICAL_dapagliflozin @CHEMICAL_MESH:C529054 @@@dapagliflozin@@@ = 168, @CHEMICAL_empagliflozin @CHEMICAL_MESH:C570240 @@@empagliflozin@@@/@CHEMICAL_Linagliptin @CHEMICAL_MESH:D000069476 @@@linagliptin@@@ = 5, @CHEMICAL_Canagliflozin @CHEMICAL_MESH:D000068896 @@@canagliflozin@@@/@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ = 8, @CHEMICAL_Canagliflozin @CHEMICAL_MESH:D000068896 @@@canagliflozin@@@ = 503, @CHEMICAL_empagliflozin @CHEMICAL_MESH:C570240 @@@empagliflozin@@@ = 38, and @CHEMICAL_dapagliflozin @CHEMICAL_MESH:C529054 @@@dapagliflozin@@@/@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin HCl@@@ ER = 5. ", "citations": {"NLM": "Mohammad H, Borja-Hart N. Pharmacovigilance of Sodium-Glucose Cotransporter-2 Inhibitors for Genital Fungal Infections and Urinary Tract Infections: A Review of the Food and Drug Administration Adverse Event Reporting System Database. J Pharm Technol. 2018 Aug;34(4):144-148. PMID: 34860970", "BibTeX": "@article{34860970, title={Pharmacovigilance of Sodium-Glucose Cotransporter-2 Inhibitors for Genital Fungal Infections and Urinary Tract Infections: A Review of the Food and Drug Administration Adverse Event Reporting System Database.}, author={Mohammad H and Borja-Hart N}, journal={J Pharm Technol}, volume={34}, number={4}, pages={144-148}}"}}, {"_id": "22666947", "pmid": 22666947, "title": "Managing diabetes in India: paradigms in care--outcomes and analysis in a comprehensive, clinical practice survey of Indian physicians.", "journal": "J Indian Med Assoc", "authors": ["Sadikot SM", "Singh V"], "date": "2011-11-01T00:00:00Z", "meta_date_publication": "2011 Nov", "meta_volume": "109", "meta_issue": "11", "meta_pages": "839-42, 844-8", "score": 50046.168, "text_hl": "Around 94% of doctors chose @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ as the drug of choice for the management of this @SPECIES_9606 @@@patient@@@. ", "citations": {"NLM": "Sadikot SM, Singh V. Managing diabetes in India: paradigms in care--outcomes and analysis in a comprehensive, clinical practice survey of Indian physicians. J Indian Med Assoc. 2011 Nov;109(11):839-42, 844-8. PMID: 22666947", "BibTeX": "@article{22666947, title={Managing diabetes in India: paradigms in care--outcomes and analysis in a comprehensive, clinical practice survey of Indian physicians.}, author={Sadikot SM and Singh V}, journal={J Indian Med Assoc}, volume={109}, number={11}, pages={839-42, 844-8}}"}}, {"_id": "26921394", "pmid": 26921394, "title": "High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ~240-Fold Higher Drug Concentration in Urine than Serum.", "journal": "Mol Cancer Ther", "authors": ["Liu Z", "Yokoyama NN", "Blair CA", "Li X", "Avizonis D", "Wu XR", "Uchio E", "Youssef R", "McClelland M", "Pollak M", "Zi X"], "date": "2016-03-01T00:00:00Z", "doi": "10.1158/1535-7163.MCT-15-0714-T", "meta_date_publication": "2016 Mar", "meta_volume": "15", "meta_issue": "3", "meta_pages": "430-8", "score": 50042.49, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ significantly improved survival, reduced @<m>DISEASE_Urinary_Tract_Infections</m> @DISEASE_MESH:D014552 @@@urinary tract obstruction@@@, reduced bladder weight (a surrogate for @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumor@@@ volume), and led to clear activation of AMP alpha kinase and inhibition of @GENE_MTOR @GENE_56717 @@@mTOR@@@ signaling in neoplastic tissue. ", "citations": {"NLM": "Liu Z, Yokoyama NN, Blair CA, Li X, Avizonis D, Wu XR, Uchio E, Youssef R, McClelland M, Pollak M, Zi X. High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ~240-Fold Higher Drug Concentration in Urine than Serum. Mol Cancer Ther. 2016 Mar;15(3):430-8. PMID: 26921394", "BibTeX": "@article{26921394, title={High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ~240-Fold Higher Drug Concentration in Urine than Serum.}, author={Liu Z and Yokoyama NN and Blair CA and Li X and Avizonis D and Wu XR and Uchio E and Youssef R and McClelland M and Pollak M and Zi X}, journal={Mol Cancer Ther}, volume={15}, number={3}, pages={430-8}}"}}, {"_id": "24722494", "pmid": 24722494, "title": "Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.", "journal": "Diabetes Care", "authors": ["Häring HU", "Merker L", "Seewaldt-Becker E", "Weimer M", "Meinicke T", "Broedl UC", "Woerle HJ", "EMPA-REG MET Trial Investigators"], "date": "2014-06-01T00:00:00Z", "doi": "10.2337/dc13-2105", "meta_date_publication": "2014 Jun", "meta_volume": "37", "meta_issue": "6", "meta_pages": "1650-9", "score": 50039.688, "text_hl": "@CHEMICAL_empagliflozin @CHEMICAL_MESH:C570240 @@@Empagliflozin@@@ as add-on to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@: a 24-week, randomized, double-blind, placebo-controlled trial.", "citations": {"NLM": "Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ, EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014 Jun;37(6):1650-9. PMID: 24722494", "BibTeX": "@article{24722494, title={Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.}, author={Häring HU and Merker L and Seewaldt-Becker E and Weimer M and Meinicke T and Broedl UC and Woerle HJ and EMPA-REG MET Trial Investigators}, journal={Diabetes Care}, volume={37}, number={6}, pages={1650-9}}"}}]}